Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Janus kinase inhibitors may help treat lichen planopilaris.

Tofacitinib helped a woman regrow hair with no major side effects.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

WYE-130600 may cause skin thickening and irritation.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Topical Ruxolitinib may safely treat severe hair loss.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Cinacalcet may help treat hereditary vitamin D resistant rickets safely.

Baricitinib may effectively treat lichen planopilaris.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.